Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Califf Sets Departure From US FDA; Ostroff May Become Interim Leader

Executive Summary

As FDA Commissioner Robert Califf prepares to step down from his post to make way for a Trump administration replacement, former Acting Commissioner Stephen Ostroff may step into the breach.

You may also be interested in...



Califf Closes In On Reprising His FDA Role After Senate Committee Hearing

After a mostly friendly round of questioning from members of the US Senate committee on health, the confirmation of President Joe Biden’s pick to lead the US FDA seems more likely.

Robert Califf Nominated To Retake FDA Commissioner Role

President Biden’s pick for FDA commissioner should remember many of the hot-button issues that he would face if confirmed to a second stint as the nation's top medtech regulator.

Possible Trump FDA Commish Candidate Favors (Much) Lighter Touch

The Trump transition team is considering Jim O'Neill, a Silicon Valley investment manager, to head US FDA, according to news reports. Previous comments from O'Neill – who has some HHS experience – suggest, he favors substantially reducing FDA's role in assessing product effectiveness. While some experts are highly skeptical about O'Neill, others suggest he could champion much-needed change at the agency.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT104278

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel